Shelly A. McNeil
Dalhousie University
219 Papers
791 Citations
Shelly A. McNeil is an academic researcher from Dalhousie University. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 43, co-authored 206 publications. Previous affiliations of Shelly A. McNeil include University of Michigan & United States Department of Veterans Affairs.
Chat about Author
Papers
Q Fever Update, Maritime Canada
TL;DR: In this paper, passive surveillance for Q fever in Nova Scotia and its neighboring provinces in eastern Canada indicates that the clinical manifestation of Q fever is pneumonia and that incidence of the disease may fluctuate.
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
Nicolas Folschweiller,Ulrich Behre,Marc Dionne,Paolo Durando,Susanna Esposito,Linda Ferguson,Murdo Ferguson,Peter Hillemanns,Shelly A. McNeil,Klaus Peters,Brian Ramjattan,Tino F. Schwarz,Khuanchai Supparatpinyo,Pemmaraju V Suryakirian,Michel Janssens,Philippe Moris,Annabelle Decreux,Sylviane Poncelet,Frank Struyf +18 more
TL;DR: This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years and in women aged 15–25 years.
A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age
Joanne M. Langley,Joanne M. Langley,Elodie Pastural,Scott A. Halperin,Scott A. Halperin,Shelly A. McNeil,Shelly A. McNeil,May Elsherif,Donna MacKinnon-Cameron,Lingyun Ye,Cecile Grange,Valérie Thibodeau,Jean-François Cailhier,Réjean Lapointe,Janet E. McElhaney,Luis Martin,Marilène Bolduc,Marie-Eve Laliberté-Gagné,Denis Leclerc,Pierre Savard +19 more
TL;DR: The Papaya Mosaic Virus adjuvant in doses of 30 to 240 µg combined with reduced influenza antigen content was safe with no signals up to 3 years after vaccination and immunogenicity results suggest that efficacy study should be conducted in influenza antigen-naïve participants.
10
Sources of viral respiratory infections in Canadian acute care hospital healthcare personnel.
S. Buckrell,Brenda L. Coleman,Shelly A. McNeil,Kevin Katz,Kevin Katz,Matthew P. Muller,Andrew E. Simor,Andrew E. Simor,Mark Loeb,Jeff Powis,Stefan P. Kuster,J.M. Di Bella,K.K.L. Coleman,Steven J. Drews,Steven J. Drews,Philipp Kohler,A. McGeer,Todd F. Hatchette,L. Holness,Janet Raboud,Joanne M. Langley,Tony Mazzulli,K. Nichol,L. Genesove,John Oudyk,L. McCaskell,N. Johnson +26 more
TL;DR: Community and co-worker contacts are important sources of viral respiratory illness in healthcare personnel, while exposure to patients with recognized respiratory infections is not associated.
10
Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network
Melissa K. Andrew,H Pott,Lisa Staadegaard,John Paget,Sandra S. Chaves,Justin R. Ortiz,John W. McCauley,Joe Bresee,Marta C. Nunes,Elsa Baumeister,Sonia Mara Raboni,H.I. Garcia Giamberardino,Shelly A. McNeil,Doris Gómez,Tao Zhang,Philippe Vanhems,Parvaiz A Koul,D. Coulibaly,Nancy A. Otieno,Ghassan Dbaibo,Maria De lourdes Guerrero Almeida,V. Alberto Laguna-Torres,Anca Drăgănescu,Elena Burtseva,Anna Sominina,Daria Danilenko,Snežana Medić,Javier Díez-Domingo,Bruno Lina +28 more
TL;DR: In this article , a multivariate logistic regression model was used to analyze the extent to which various risk factors predict severe outcomes in patients who were hospitalized with influenza and the effect of influenza vaccination on adverse clinical outcomes.
10